Skip to main content

Shearman & Sterling, Fangda Partners and Tian Yuan Law Firm have advised Chinese cancer cell therapy developer JW Therapeutics on its $300 million IPO in Hong Kong, with Davis Polk & Wardwell and Commerce & Finance Law Offices counselling the joint sponsors and underwriters.

JW Therapeutics is a clinical stage cell therapy platform company, founded by Juno Therapeutics and WuXi AppTec in 2016, and focused on developing, manufacturing and commercialising breakthrough cell-based immunotherapies for hematological cancers and solid tumours.

The listing is the latest in the recent flurry of biotech IPOs in Hong Kong. Other recent issuers in the city include Simcere Pharmaceutical Group, JHBP (CY) Holdings and Everest Medicines.

The Shearman team was led by partners Kyungwon (Won) Lee and Max Hua.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com. 

Related Articles

Deals

9 firms advise on milestone $8.2 bln cross-border insurance deal

by Sarah Wong |

Global law firms Debevoise & Plimpton, Kirkland & Ellis and Herbert Smith Freehills are acting for Bermuda-based insurer Resolution Life on its $8.2 billion sale to Japan’s Nippon Life Insurance, the largest overseas acquisition by a Japanese insurer to date.

Deals

Top international firms act on landmark $7.1 bln ESR take-private deal

by Nimitt Dixit |

Global law firms Freshfields, Latham & Watkins, Kirkland & Ellis, Paul, Weiss, Rifkind, Wharton & Garrison and Cleary Gottlieb Steen & Hamilton have steered an offer to take the Hong Kong-listed ESR Group private in a deal valued at $7.1 billion.

Deals

Fangda, KWM act on HKAA’s $592 mln acquisition of Zhuhai Airport stake

by Hu Yangxiaoxiao 胡阳潇潇 |

Fangda Partners has advised the Hong Kong Airport Authority (HKAA) on its agreement to purchase a 35 percent stake in Zhuhai Airport for approximately $592 million, with King & Wood Mallesons representing the seller, Zhuhai Transportation.